ReviewCancers2026
Ubiquitination-Dependent Cyclin Regulation in Gastric Cancer and Emerging Targeted Therapies with Chinese Herbal Bioactive Compounds.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gastric cancer (GC) remains one of the most prevalent malignancies worldwide, with a high mortality rate primarily attributable to late-stage diagnosis and limited therapeutic options. Aberrant cell proliferation arising from cell cycle dysregulation is a hallmark of GC pathogenesis. Cyclins, as core regulators of cell cycle progression, exhibit dynamic protein expression patterns that are tightly controlled by the ubiquitin-proteasome system (UPS). In GC, cyclins are frequently overexpressed due to impaired ubiquitination and subsequent proteasomal degradation. This review systematically elucidates the ubiquitination-mediated regulation of distinct cyclins (Cyclins D, E, A, and B) at specific cell cycle phases-G1, S, G2, and M-and highlights the critical roles of E3 ubiquitin ligases, including SCF complexes and APC/C, in GC progression. We further discuss how dysregulated non-coding RNAs and altered E3 ligase expression contribute to aberrant cyclin ubiquitination, thereby promoting GC cell proliferation, metastasis, and poor prognosis. Importantly, emerging evidence demonstrates that bioactive compounds derived from traditional Chinese medicine (TCM) can counteract these abnormalities by directly downregulating cyclin expression, modulating E3 ligase activity, or inhibiting 26S/20S proteasome function, thus restoring cell cycle homeostasis and suppressing GC growth. This review integrates molecular mechanisms of cyclin ubiquitination with TCM-based therapeutic strategies, offering novel insights into targeted interventions for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.